Suzhou Pharmaceutical Technology Co., Ltd. (China) supplies Oclacitinib API CAS 1208319-26-9 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Oclacitinib API — Overview
Oclacitinib (CAS: 1208319-26-9, also known as PF-03394197, JAKi, and Apoquel active ingredient) is a selective Janus kinase inhibitor used as a veterinary pharmaceutical API for canine allergic dermatitis and atopic dermatitis. It modulates JAK1-dependent cytokine signalling involved in pruritus and skin inflammation. Suzhou Pharmaceutical Technology Co., Ltd. supplies ≥98% Oclacitinib API in bulk from Suzhou, China, with export to South America, Australia, New Zealand, Mexico, Canada, and worldwide markets. Export documentation: COA and MSDS standard for all orders.
| Product Name | Oclacitinib |
| Structural Formula |  |
| Alias | PF-03394197; JAKi; Apoquel active ingredient; Oclacitinibum |
| CAS Number | 1208319-26-9 |
| Molecular Formula | C₁₅H₂₃N₅O₂S |
| Molecular Weight | 337.44 g/mol |
| Purity | ≥98% (HPLC) |
| Appearance | White to off-white crystalline powder |
| Storage | Below 25°C, protected from light and moisture |
> Applications
Oclacitinib inhibits Janus kinase pathways involved in itch and inflammatory signalling, with particular relevance to JAK1-dependent cytokines such as interleukin-31. In veterinary dermatology, this mechanism helps reduce pruritus rapidly while avoiding the broad systemic effects associated with long-term corticosteroid use. Oclacitinib API is used by veterinary pharmaceutical companies, compounding pharmacies, and research organizations for oral canine dermatology formulations where local regulations permit.
Canine allergic and atopic dermatitis
Oclacitinib is used for control of pruritus associated with allergic dermatitis and for management of atopic dermatitis in dogs. In a randomized, double-blinded, placebo-controlled field trial (Veterinary Dermatology, 2013, doi:10.1111/vde.12047, n=436 dogs), oclacitinib provided rapid control of pruritus and associated skin lesions compared with placebo. In another randomized clinical trial against ciclosporin (Veterinary Dermatology, 2015, doi:10.1111/vde.12186, n=226 dogs), oclacitinib showed faster pruritus reduction through day 28 and fewer gastrointestinal adverse events than ciclosporin.
Veterinary formulation and research use
Oclacitinib is commonly formulated as oral tablets for prescription veterinary use. API buyers usually evaluate assay, related substances, residual solvents, particle size, and stability data before moving from sample quantities to pilot or commercial batches. For research groups, Oclacitinib is also used as a tool compound for studying JAK-dependent cytokine pathways in canine dermatology models.
> Sourcing & Supply
Suzhou Pharmaceutical Technology Co., Ltd. is an R&D-driven pharmaceutical company with in-house synthesis and analytical capability for Oclacitinib API. Small batches (up to 10 kg) are produced directly by our technical team in Suzhou. For larger commercial quantities, production is scaled up at qualified manufacturing facilities, with export documentation provided according to the order scope.
- Small-batch orders (≤10 kg): synthesized by our technical team in Suzhou. Lead time 10–14 business days from order confirmation.
- Commercial bulk (>10 kg): scaled up at qualified manufacturing facilities. Lead time 14–21 business days depending on batch size and documentation.
We export Oclacitinib API to buyers across South America — including Brazil, Argentina, Colombia, Chile, Peru, Ecuador, Bolivia, and Uruguay — as well as to Australia, New Zealand, Mexico, and Canada. Inquiries from European, Middle Eastern, and Asian markets are also welcome.
> Quality & Export Documentation
All Oclacitinib shipments are accompanied by a Certificate of Analysis (COA) confirming identity, appearance, assay, and related substances against batch specification. Purity is tested by HPLC against an authenticated reference standard. MSDS is provided for all orders, and Certificate of Origin (COO) is available for commercial bulk shipments.
| Order size | Documentation included |
| ≤10 kg (small-batch / research) | COA + MSDS |
| >10 kg (commercial bulk) | COA + MSDS + COO |
> Packaging & Logistics
- 100 g, 500 g: double-layered aluminium foil bag, heat-sealed, nitrogen-purged
- 1 kg: aluminium foil bag inside kraft paper box
- 5 kg, 10 kg: aluminium foil bag inside fibre drum
- >10 kg: packaging agreed according to commercial order requirements
Oclacitinib API is shipped with moisture-protective packaging and batch labels matched to the COA. Shipping options include express courier for sample and kilogram quantities, air freight for 1–10 kg orders, and sea freight for larger commercial shipments where timing allows.
> Pricing & Supply
Oclacitinib pricing is provided on request. We do not publish list prices because the final quote depends on order quantity, purity requirement, documentation needs, shipping destination, and current raw material costs.
- MOQ: 100 g for qualified buyers
- Sample policy: 10–50 g samples available for formulation evaluation or analytical confirmation
- Bulk discount tiers apply at 500 g, 1 kg, 5 kg, and 10 kg
- Payment: T/T (bank transfer). 100% in advance for standard orders. Terms for larger repeat orders by arrangement.
> Frequently Asked Questions
What is the minimum order quantity for Oclacitinib API?
The minimum order quantity for Oclacitinib API is 100 grams. Sample quantities of 10–50 g are available for qualified buyers before pilot or commercial orders. Orders of 1 kg or more qualify for bulk pricing with COA and MSDS included.
What documents are included with an Oclacitinib bulk order?
All Oclacitinib orders include a COA and MSDS in English. For commercial bulk orders above 10 kg, COO is available as standard export documentation. Additional documents depend on the specific product, destination, and order quantity.
Can I request an Oclacitinib sample before placing a bulk order?
Yes. Sample quantities of 10–50 g are available for qualified buyers. Samples are normally dispatched within 7 business days of inquiry confirmation and are shipped by express courier. Please include your intended use, quantity target, and destination country when requesting a sample.
Do you export Oclacitinib API to South America?
Yes. We regularly support Oclacitinib API inquiries from buyers in Brazil, Argentina, Colombia, Chile, Peru, Ecuador, Bolivia, and Uruguay. Lead time is typically 10–20 business days depending on destination and order size. COA, MSDS, and COO are available for commercial exports to this region.
Can buyers in Australia, New Zealand, Mexico, or Canada order Oclacitinib?
Yes. We supply Oclacitinib API to buyers in Australia, New Zealand, Mexico, and Canada. Air freight to Australia and New Zealand typically takes 5–8 business days; to Mexico and Canada 5–7 business days. COA and MSDS are included with all orders.
What is Oclacitinib used for in veterinary medicine?
Oclacitinib is used in veterinary medicine to control pruritus associated with allergic dermatitis and to manage atopic dermatitis in dogs. It is the active pharmaceutical ingredient in Apoquel, a prescription veterinary product marketed for canine dermatology. API supply is intended for qualified pharmaceutical, compounding, or research buyers.
What is the mechanism of action of Oclacitinib?
Oclacitinib inhibits Janus kinase signalling involved in itch and inflammatory cytokine pathways. It is especially relevant to JAK1-dependent cytokines such as interleukin-31, which is strongly associated with pruritus in dogs. This targeted mechanism helps reduce itch and skin inflammation in canine allergic disease.
Is Apoquel the same as Oclacitinib?
Apoquel is a finished veterinary medicine whose active ingredient is Oclacitinib. Oclacitinib API from Suzhou Pharmaceutical Technology Co., Ltd. is supplied as the bulk active pharmaceutical ingredient, not as a finished tablet. Buyers are responsible for confirming local regulatory requirements before formulation or resale.
What purity is available for Oclacitinib CAS 1208319-26-9?
Our standard Oclacitinib API specification is ≥98% purity by HPLC. Each batch is released with a COA covering assay, appearance, related substances, and other agreed specification items. Additional analytical items can be discussed before order confirmation.
Do you supply Oclacitinib to Southeast Asia and the Middle East?
Yes. Oclacitinib API is available for buyers in Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines, UAE, Saudi Arabia, Turkey, Israel, and other countries in these regions. Lead time is typically 7–14 business days by express courier for sample and small-batch orders.
How is Oclacitinib packaged and shipped internationally?
Oclacitinib API is shipped in double-layered, nitrogen-purged aluminium foil bags for quantities up to 1 kg and in foil-lined fibre drums for larger orders. Packaging is selected to protect the material from moisture and light during international transit.
> Related Products
- Pimobendan | CAS 74150-27-9 — Veterinary inodilator API for canine heart failure
- Maropitant | CAS 147116-67-4 — NK-1 antagonist for canine vomiting and nausea
- Clomipramine | CAS 303-49-1 — Veterinary behavioral medicine API
- Tacrolimus | CAS 104987-11-3 — Immunomodulatory API for dermatology and ophthalmic use
> Request a Quote or Sample
To request a quote or sample for Oclacitinib API (CAS 1208319-26-9), please contact us directly at Info@fmyykj.com.
Include in your inquiry: required quantity (grams or kg), destination country, documentation requirements (COA + MSDS standard; COO for bulk), and intended use (veterinary formulation / compounding / research / other). We respond to all inquiries within 1 business day.
Last reviewed: June 2026